Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 11;13(12):2485. doi: 10.3390/v13122485

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Neutralization of variant SARS-CoV-2 pseudoviruses by therapeutic antibodies. The antibody panel, consisting of 15 single neutralizing Abs (nAbs A–R), six combination Abs (S–X), and two polyclonal Abs (III–IV), were tested against SARS-CoV-2 pseudoviruses bearing the indicated spike proteins. Only those that displayed significant neutralization resistance compared to WT(D614G) are shown (Refer to Supplementary Figure S4 for remaining antibodies). Antibodies are blinded according to an agreement with the manufacturers. The neutralization titer (IC₅₀) ratios of the B.1.617.1 variants (A), B.1.617.2 variant (B), and AY.1 variant (C) relative to WT(D614G) are plotted. The dotted lines represent the neutralization titer ratio of 10. *: complete resistance at the highest concentration tested (>50-fold change of IC₅₀).